Home › NDC Lookup › RxCUI directory › RxCUI 2284515

Cysteamine 75 MG Delayed Release Oral Granules — RxCUI 2284515

RxNorm drug concept · Semantic clinical drug
RxCUI 2284515 Semantic clinical drug · SCD ● Current RxNorm concept 4 FDA products 6 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2284515
Official nameCysteamine 75 MG Delayed Release Oral Granules
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known ascysteamine (as cysteamine bitartrate) 75 MG Delayed Release Oral Granules
FDA products mapped4
Package NDCs mapped6
Reported Medicaid activity (SDUD)403 prescriptions · 9 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Cysteamine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Cystinosis is a rare inherited condition where your body can't properly move a substance called cystine out of the recycling compartments inside your cells. Over time, cystine buil...
  • What exactly is cystinosis, and why do I need this medication for life?
  • Your doctor will measure cystine levels in your white blood cells regularly — usually about 5 to 6 hours after a dose. These levels tell your doctor whether the dose is in the righ...
  • How do I know if the medication is working?
📖 Read our full Cysteamine guide →

🕸️ Concept Web — How Cysteamine 75 MG Delayed Release Oral Granules Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Cysteamine 75 MG Delayed Release Oral Granules RxCUI 2284515

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Cysteamine 3022
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Procysbi 1421468
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Cysteamine Delayed Release Oral Granules 2284509
    • Cysteamine Granule Product 2284508
    • Cysteamine Oral Product 1151468
    • Cysteamine Delayed Release Oral Granules [Procysbi] 2284512
    • Procysbi Granule Product 2284513
    • Procysbi Oral Product 1421471
    • Delayed Release Oral Granules 2284290
    • Granule Product 1294708
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Cysteamine 75 MG SCDC · 1421474
  • Cysteamine Delayed Release Oral Granules SCDF · 2284509
  • Cysteamine Granule Product SCDG · 2284508
  • Cysteamine Oral Product SCDG · 1151468

Brand-Name Concepts

  • Cysteamine 75 MG Delayed Release Oral Granules [Procysbi] SBD · 2284516
  • Cysteamine 75 MG [Procysbi] SBDC · 1421476
  • Cysteamine Delayed Release Oral Granules [Procysbi] SBDF · 2284512
  • Procysbi Granule Product SBDG · 2284513
  • Procysbi Oral Product SBDG · 1421471
  • Procysbi BN · 1421468

📦 FDA Products & Package NDCs

4 products · 6 package NDCs
6 package NDCs map to RxCUI 2284515 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
75987-0100-04 60 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE (75987-100-0... PROCYSBI Horizon Therapeutics USA, Inc. 2013-04-30
75987-0101-08 250 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE (75987-101-... PROCYSBI Horizon Therapeutics USA, Inc. 2013-04-30
75987-0140-13 60 PACKET in 1 CARTON (75987-140-13) / 1 GRANULE, DELAYED R... PROCYSBI Horizon Therapeutics USA, Inc. 2020-02-14
75987-0140-14 120 PACKET in 1 CARTON (75987-140-14) / 1 GRANULE, DELAYED... PROCYSBI Horizon Therapeutics USA, Inc. 2020-02-14
75987-0145-13 60 PACKET in 1 CARTON (75987-145-13) / 1 GRANULE, DELAYED R... PROCYSBI Horizon Therapeutics USA, Inc. 2020-02-14
75987-0145-14 120 PACKET in 1 CARTON (75987-145-14) / 1 GRANULE, DELAYED... PROCYSBI Horizon Therapeutics USA, Inc. 2020-02-14
Observed labelers: Horizon Therapeutics USA, Inc. (6) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.